The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.Summit Therapeutics, the Florida company that has been seeking to bring the drug to the US market, disclosed the agency’s decision in a news release on Nov 15. Summit bought the US rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China.
US FDA rejects closely watched lung cancer drug from China
Full Article
Original Source
Read the full article at Straitstimes →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.